Results 181 to 190 of about 21,140 (245)

Pharmacist administration of long-acting injectable medications for substance use disorders: A scoping review. [PDF]

Ment Health Clin
Hernandez Bustamante P, Charles A, Snider M, Catanzano S.   +3 more
europepmc   +1 more source

Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis. [PDF]

EClinicalMedicine
Liu L, Li Z, Ye W, Peng P, Wang Y, Wan L, Li J, Zhang M, Wang Y, Liu R, Xu D, Zhang J.   +11 more
europepmc   +1 more source

Pain Intensity in Patients with Opioid Use Disorder on Extended-Release Naltrexone or Opioid Agonists; The Role of COMT rs4680 and OPRM1 rs1799971: An Exploratory Study. [PDF]

J Pain Res
Juya F, Sannes AC, Solli KK, Weimand B, Gjerstad J, Tanum L, Mordal J.   +6 more
europepmc   +1 more source

Barriers and facilitators to community pharmacist-provided injectable naltrexone for formerly incarcerated individuals during community reentry. [PDF]

Explor Res Clin Soc Pharm
Chladek JS, Chui MA.
europepmc   +1 more source

Unexpected Increase in Bone Mineral Density With Rapamycin and Low-Dose Naltrexone: A Case Report of a 52-Year-Old Woman With Osteopenia. [PDF]

Cureus
Britton A, Harinath G, Morgan S, Zalzala S.   +3 more
europepmc   +1 more source

Corrigendum to "Receipt of medication for opioid use disorder among rural and urban veterans health administration patients" [Drug Alcohol Depend. Rep. 14 (2025) 100311]. [PDF]

Drug Alcohol Depend Rep
Reynolds OC, Carlson KF, Gordon AJ, Handley RL, Morasco BJ, Korthuis TP, Lovejoy TI, Wyse JJ.   +7 more
europepmc   +1 more source

Potential Cardiovascular Risks Associated with Naltrexone-Bupropion Treatment in Overweight Patients [Letter]. [PDF]

Drug Des Devel Ther
Wu L, Hu J, Yao P.
europepmc   +1 more source

Assessing the comparative effectiveness of ECHO and coaching implementation strategies in a jail/provider MOUD implementation trial. [PDF]

Implement Sci
Molfenter T, Vechinski J, Kim JS, Zhang J, Meng L, Tveit J, Madden L, Taxman FS.   +7 more
europepmc   +1 more source

Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails.

JAMA Netw Open
Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, Pollack HA, Schneider JA.   +7 more
europepmc   +1 more source

Impact of Intracellular Proteins on μ-Opioid Receptor Structure and Ligand Binding. [PDF]

J Phys Chem B
Scott CE, Juechter LA, Rocha J, Jones LD, Outten B, Aishman TD, Ivers AR, Shields GC.   +7 more
europepmc   +1 more source